News on cancer. ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-presents-new-preclinical-data-supporting
Continued to run after public offering ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-closing-201-million-public
Nov started treating in clinical trial. ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-doses-first-patient-landmark-crisprcas9
Expanded collaboration with regeneron. ir.intelliatx.com/news-releases/news-release-details/regeneron-and-intellia-therapeutics-expand-collaboration-develop
Business Seems to be firing on all cylinders.
Technically looks over extended.
Continued to run after public offering ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-closing-201-million-public
Nov started treating in clinical trial. ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-doses-first-patient-landmark-crisprcas9
Expanded collaboration with regeneron. ir.intelliatx.com/news-releases/news-release-details/regeneron-and-intellia-therapeutics-expand-collaboration-develop
Business Seems to be firing on all cylinders.
Technically looks over extended.
Trade attivo
>180 up since Dec. outpacing edit and crispr. still looks technically extended
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.
Declinazione di responsabilità
Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.